Perrigo Rogaine Foam ANDA May Help Extend Record Growth
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's regulatory green light to market the first OTC generic of Men's Rogaine Foam further extends the pipeline that has kept the firm on a streak of record earnings.
You may also be interested in...
In Brief
Perrigo debuts Rogaine Foam equivalent; Pfizer patent suit applies heat to J&J/McNeil; Merck KGaA consumer unit beats forecast; Abbott seeks expanded vitamin D3 use; Hi-Tech Pharmacal adds to homeopathics portfolio; more news In Brief.
Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.
Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.